Apr 1, 2014
BERGISCH GLADBACH, GERMANY, 31 March 2014 – Varian Medical Systems (NYSE: VAR) and the Paul Scherrer Institute (PSI) are announcing an extension of their existing collaboration in the field of proton therapy to offer patients more precise cancer treatments using intensity modulated proton therapy (IMPT). Under the agreement, Varian will also supply technology and equipment to help meet a growing demand for clinical research and treatments at PSI.
Proton therapy targets tumors with concentrated doses of radiation while offering superior protection of surrounding healthy tissue. IMPT, which was pioneered using pencil-beam scanning at the Paul Scherrer Institute and made commercially available by Varian Medical Systems, is a radiation delivery technique that enables clinicians to optimize precision when treating tumors.
"This multi-year R&D collaboration will enable Varian and PSI to continue their productive research activities in the areas of advanced pencil beam scanning delivery systems, on-board imaging, clinical workflow optimization, and accelerator technology to further develop proton treatment technology over the coming years," says Moataz Karmalawy, head of Varian's Particle Therapy group. "Our original collaboration led to the commercialization of IMPT and we are delighted to expand our partnership to develop more revolutionary technologies."
"Over the past ten years we have developed scanning techniques for the treatment of tumors with intensity-modulated proton therapy," adds Prof. Dr. Joel Mesot, director of the Paul Scherrer Institute. "We are looking forward to the new collaboration as it will help us to develop more tools for treating more patients with even greater precision while making our technology more widely available to the clinical and scientific community."
The value of the equipment portion of the contract is approximately $10 million and it will be booked in the second quarter of fiscal 2014.
Varian's scanning beam IMPT technology is already being used at the Scripps Proton Therapy Center in San Diego, U.S., and the Rinecker Proton Therapy Center in Munich, Germany. Varian also has contracts to install ProBeam systems at six additional sites in the U.S., Saudi Arabia, and Russia.
*CE mark and international registrations pending for ProBeam. Not available for sale in all markets.
©
March 30, 2014
Radiance 330 proton therapy system to be installed at MGH
Flower Mound, TX, 27 March 2014 – ProTom International, Inc. ("ProTom") is pleased to announce the execution of a purchase agreement with Massachusetts General Hospital ("MGH") for the acquisition of a Radiance 330® Proton Therapy System ("Radiance 330") to be housed in the MGH Department of Radiation Oncology. Under the terms of the contract, ProTom will supply a single treatment room configuration including its compact 330 MeV synchrotron accelerator and 180-degree gantry with robotic patient positioner.
The Radiance 330 is equipped with ProTom's Fidelity™ Beam Scanning System, innovative technology designed and optimized for discrete scanning. This type of scanning accurately "paints" the tumor with the physician-prescribed proton dose using magnetic steering to guide lateral dose deposition and beam energy variations -- changed within a second, with sub-millimeter accuracy -- to control penetration depth. This highly sophisticated 3-dimensional beam scanning technique enables the physician to exploit the dose control advantages of protons to their full potential, even for the most complex cases.
At MGH the entire system will be installed inside a radiation-shielded vault embedded within the existing radiation oncology department -- a solution that enables the facility to share clinical staff, ancillary equipment, and patient support areas. The Radiance 330 synchrotron can be installed within an interior accelerator vault space of 20' x 30' and requires up to 40% less radiation shielding than many other systems on the market today. The lighter-weight, compact technology simplifies the installation process; and the largest component of any system configuration (fixed beam, 180 degree gantry, etc.) requires no special road transport, facility hatch, or extraordinary cranes and can be moved in through typical freight or staff entrances.
The design of the Radiance 330 allows health care providers to develop single or multiple-room capability within or adjacent to an existing radiation oncology department; and its beam transport design supports both horizontal and vertical beam lines to accommodate a multi-level layout where space constraints may dictate that treatment room(s) and the accelerator be located on different floors.
©
The Radiance 330 is equipped with ProTom's Fidelity™ Beam Scanning System, innovative technology designed and optimized for discrete scanning. This type of scanning accurately "paints" the tumor with the physician-prescribed proton dose using magnetic steering to guide lateral dose deposition and beam energy variations -- changed within a second, with sub-millimeter accuracy -- to control penetration depth. This highly sophisticated 3-dimensional beam scanning technique enables the physician to exploit the dose control advantages of protons to their full potential, even for the most complex cases.
At MGH the entire system will be installed inside a radiation-shielded vault embedded within the existing radiation oncology department -- a solution that enables the facility to share clinical staff, ancillary equipment, and patient support areas. The Radiance 330 synchrotron can be installed within an interior accelerator vault space of 20' x 30' and requires up to 40% less radiation shielding than many other systems on the market today. The lighter-weight, compact technology simplifies the installation process; and the largest component of any system configuration (fixed beam, 180 degree gantry, etc.) requires no special road transport, facility hatch, or extraordinary cranes and can be moved in through typical freight or staff entrances.
The design of the Radiance 330 allows health care providers to develop single or multiple-room capability within or adjacent to an existing radiation oncology department; and its beam transport design supports both horizontal and vertical beam lines to accommodate a multi-level layout where space constraints may dictate that treatment room(s) and the accelerator be located on different floors.
©
March 20, 2014
ProTom International, Inc. Receives FDA 510(k) Clearance for its Radiance 330® Proton Therapy System
March 19, 2014
FLOWER MOUND, Texas--(BUSINESS WIRE)--ProTom International, Inc., the developer and manufacturer of a technologically advanced proton beam radiation therapy system, announced today it has received 510(k) clearance for its Radiance 330 Proton Therapy System. The Radiance 330 is a compact, modular and more affordable proton beam delivery system for the treatment of patients with cancer. The system delivers extremely focused, conformal, scanned proton beams that destroy tumors while sparing nearby healthy tissue and anatomical structures. The system’s modular design easily accommodates the buyer’s preferences for 3-D imaging solutions and treatment planning software through industry-standard interfaces. The compact accelerator can be installed within an interior vault space of approximately 20’ x 30’ and requires up to 40% less radiation shielding than many other systems on the market today. The Radiance 330 can be configured using its single, energy-efficient synchrotron to operate a single or multiple treatment room facility; treatment rooms can be equipped with isocentric gantries or as fixed-beam lines with one or more ports.
Steve Spotts, Chief Executive Officer and co-founder of ProTom International, commented, “The receipt of 510(k) clearance is the final culmination of a thorough and rigorous FDA review of the safety and effectiveness of the Radiance 330. This achievement accelerates our team’s single and relentless mission to place this highly sophisticated and targeted cancer-fighting tool within reach of many more physicians. Our team couldn’t be more proud of reaching this milestone and will continue our work to advance the delivery of proton therapy while driving down the cost of this much needed technology.”
About ProTom International, Inc.
ProTom is a privately-held company, developing innovative and affordable solutions for proton radiation therapy. ProTom has offices in Flower Mound, Texas and Wakefield, Massachusetts. Its Engineering, Physics, Clinical, Operational and IT leadership experience collectively spans 150 years in healthcare, with more than 75 years of combined experience in proton therapy. Developing and delivering highly sophisticated proton therapy technology is not only what we do, it is all we do. Our medical device operations are headquartered in the USA — from which all of our design, manufacturing, and service divisions are currently managed and operated. To find out more about the future of proton therapy, visit us at www.protominternational.com.
Contacts
ProTom International, Inc.
Thomas Carman, 972-410-3551 x2008
SVP Sales and Development
tcarman@protominternational.com
©
FLOWER MOUND, Texas--(BUSINESS WIRE)--ProTom International, Inc., the developer and manufacturer of a technologically advanced proton beam radiation therapy system, announced today it has received 510(k) clearance for its Radiance 330 Proton Therapy System. The Radiance 330 is a compact, modular and more affordable proton beam delivery system for the treatment of patients with cancer. The system delivers extremely focused, conformal, scanned proton beams that destroy tumors while sparing nearby healthy tissue and anatomical structures. The system’s modular design easily accommodates the buyer’s preferences for 3-D imaging solutions and treatment planning software through industry-standard interfaces. The compact accelerator can be installed within an interior vault space of approximately 20’ x 30’ and requires up to 40% less radiation shielding than many other systems on the market today. The Radiance 330 can be configured using its single, energy-efficient synchrotron to operate a single or multiple treatment room facility; treatment rooms can be equipped with isocentric gantries or as fixed-beam lines with one or more ports.
Steve Spotts, Chief Executive Officer and co-founder of ProTom International, commented, “The receipt of 510(k) clearance is the final culmination of a thorough and rigorous FDA review of the safety and effectiveness of the Radiance 330. This achievement accelerates our team’s single and relentless mission to place this highly sophisticated and targeted cancer-fighting tool within reach of many more physicians. Our team couldn’t be more proud of reaching this milestone and will continue our work to advance the delivery of proton therapy while driving down the cost of this much needed technology.”
About ProTom International, Inc.
ProTom is a privately-held company, developing innovative and affordable solutions for proton radiation therapy. ProTom has offices in Flower Mound, Texas and Wakefield, Massachusetts. Its Engineering, Physics, Clinical, Operational and IT leadership experience collectively spans 150 years in healthcare, with more than 75 years of combined experience in proton therapy. Developing and delivering highly sophisticated proton therapy technology is not only what we do, it is all we do. Our medical device operations are headquartered in the USA — from which all of our design, manufacturing, and service divisions are currently managed and operated. To find out more about the future of proton therapy, visit us at www.protominternational.com.
Contacts
ProTom International, Inc.
Thomas Carman, 972-410-3551 x2008
SVP Sales and Development
tcarman@protominternational.com
©
Subscribe to:
Posts (Atom)